You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NEWS / CORPORATE / .........

CORPORATE - 30-04-2015

Kedrion SpA’s Shareholders approve 2014 financial statement

On 27th April 2015, Kedrion SpA’s Shareholders’ Meeting approved the 2014 financial statement. A 466 million euros’ turnover with a 9,8% rise on 2013, international sales accounting for 67,9% of the overall turnover, a 23,8% adjusted EBITDA, a net profit of 42 million euros: here are the key figures of 2014’s statement of accounts for Kedrion SpA.

The company showed its usual bent for expansion on the global markets in 2014 as well, above all in the United States where it exceeded 159 million euros this year.

For more information please contact: